Gilead Sciences Inc. share price logo

Gilead Sciences Inc.

NASDAQ: GILD

Large Cap

$135.88

+0.11

(+0.08%)

as on

Gilead Sciences Inc. Stock Performance

as on August 13, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $133.32
    $137.12
    downward going graph

    1.88%

    Downside

    0.91%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $108.46
    $157.29
    downward going graph

    20.18%

    Downside

    15.76%

    Upside

    downward going graph

Gilead Sciences Inc. share price movements today

Previous Close
$135.77
Open
$134.14
Volume
3.4M
Day's Low - High
$133.32 - $137.12
52 Week Low - High
$108.46 - $157.29

Gilead Sciences Inc. Historical Returns

1 Month Return
+ 3.33 %
3 Month Return
+ 2.04 %
1 Year Return
+ 13.01 %
3 Year Return
+ 69.71 %
5 Year Return
+ 90.8 %

Gilead Sciences Inc. Stock Fundamentals & Key Indicators

Check Gilead Sciences Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$165.0B

EPS (TTM)

-0.4698

Dividend Yield

2.42%

Quarterly Earnings Growth YOY

0.55%

PE Ratio (TTM)

0

PEG Ratio

2.1441

EBITDA

14.6B

Revenue (TTM)

30.5B

Profit Margin

-10.64%

Return On Equity TTM

-20.68%

Gilead Sciences Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gilead Sciences Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Gilead Sciences Inc. image
Gilead Sciences Inc.
HOLD$165.0B90.8%NA-10.64%2.42%
Eli Lilly & Co. image
Eli Lilly & Co.
BUY$1.1T359.87%39.8433.53%0.54%
AstraZeneca PLC image
AstraZeneca PLC
BUY$251.1B171.46%24.1717.02%2%
ABBVIE INC. image
ABBVIE INC.
BUY$438.2B114.71%69.469.80%2.78%
Johnson & Johnson image
Johnson & Johnson
BUY$630.9B47.4%30.0221.48%2.02%
See all

Stock Returns calculator for Gilead Sciences Inc. Stock including INR - Dollar returns

The Gilead Sciences Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Gilead Sciences Inc. investment value today

Current value as on today

₹1,23,060

Returns

₹23,060

(+23.06%)

Returns from Gilead Sciences Inc. Stock

₹13,101 (+13.1%)

Dollar Impact

₹9,959 (+9.96%)

Analyst Recommendation on Gilead Sciences Inc. Stock

Based on 38 analysts

HOLD

47.37%

Buy

52.63%

Hold

0.00%

Sell

Based on 38 analysts, 52.63% of analysts recommend a 'HOLD' rating for Gilead Sciences Inc.. Average target price of $157.41

Gilead Sciences Inc. Share Price Target

Get share price movements and forecasts by analysts on Gilead Sciences Inc..

What analysts predicted

13.68%UPSIDE

Target Price

$157.41

Current Price

$135.88

Analyzed by

38 Analysts

Target

$157.41

Gilead Sciences Inc. target price $157.41, a slight upside of 13.68% compared to current price of $135.88. According to 38 analysts rating.

Indian Investors' Interest in Gilead Sciences Inc. Stock

Search interest for Gilead Sciences Inc. Stock has increased by 13% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:13% versus previous 30 day period

Gilead Sciences Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
6,686
6,953
7,545
7,569
6,667
7,081
7,769
7,924
6,960
7,803
Gross Profit
5,134
5,409
5,971
5,988
5,127
5,580
6,200
6,300
5,515
6,224
Operating Income
-4,322
2,644
888
2,452
2,237
2,474
3,327
2,988
2,692
-10,394
EBITDA
-3,542
2,984
1,884
3,109
2,605
3,374
4,583
3,020
3,509
-10,007
Interest Expense
254
237
238
249
260
254
256
255
240
247
Depreciation
690
694
690
693
696
691
686
687
689
698
Income Before Tax
-4,486
2,053
956
2,167
1,649
2,429
3,641
2,078
2,580
-10,254
Income Tax Expense
-315
438
-297
385
334
468
589
-105
559
242
Net Income
-4,170
1,614
1,253
1,783
1,315
1,960
3,052
2,183
2,021
-10,496
Net Profit Margin
-62.37%
23.21%
16.61%
23.56%
19.72%
27.68%
39.28%
27.55%
29.04%
-134.51%

Gilead Sciences Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
30,390
26,107
22,127
22,449
24,689
27,305
27,281
27,116
28,754
29,442
Gross Profit
26,129
21,736
17,274
17,774
20,117
20,704
21,624
27,116
22,503
23,208
Operating Income
17,633
14,124
8,200
4,287
4,071
9,918
7,330
7,605
1,662
11,701
EBITDA
19,219
15,933
10,305
7,559
4,133
11,329
8,852
7,605
4,434
13,580
Interest Expense
964
1,118
1,077
995
984
1,001
935
944
977
1,024
Depreciation
-
1,286
1,429
1,404
1,480
2,050
2,103
2,533
2,767
2,760
Income Before Tax
17,097
13,529
7,799
5,160
1,669
8,278
5,814
6,859
690
9,796
Income Tax Expense
3,609
8,885
2,339
-204
1,580
2,077
1,248
-1,247
211
1,286
Net Income
13,501
4,628
5,455
5,386
123
6,225
4,592
5,665
480
8,510
Net Profit Margin
44.43%
17.73%
24.65%
23.99%
0.50%
22.80%
16.83%
20.89%
1.67%
28.90%

Gilead Sciences Inc. Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
1,614
1,253
1,783
1,315
1,960
3,052
2,183
2,021
-2,021
Operating Cash Flow
1,325
4,309
2,975
1,757
827
4,108
3,327
2,544
3,573
Investing Cash Flow
-307
-710
-225
-415
-2,116
-427
-1,835
1,770
-10,347
Financing Cash Flow
-2,953
-1,379
2,260
-3,426
-1,567
-1,489
-1,263
-4,239
2,344
Change in Cash
-1,946
2,265
4,954
-2,065
-2,782
2,186
234
64
-4,449

Gilead Sciences Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
4,644
5,460
5,364
89
6,201
4,566
5,665
480
8,510
Operating Cash Flow
11,898
8,400
9,144
8,168
11,384
9,072
8,006
10,828
10,019
Investing Cash Flow
-16,069
14,355
-7,817
-14,615
-3,131
-2,466
-2,265
-3,449
-4,793
Financing Cash Flow
3,393
-12,318
-7,634
770
-8,877
-6,469
-5,125
-3,433
-7,745
Change in Cash
-641
10,352
-6,309
-5,634
-659
74
673
3,906
-2,427

Mutual Funds that own Gilead Sciences Inc. Stock

Check out the Mutual Funds with significant holdings in Gilead Sciences Inc..

Global Institutional Holdings in Gilead Sciences Inc.

Funds
Holdings
BlackRock Inc
9.6%
Amvescap Plc.
3.35%
Dimensional Fund Advisors, Inc.
0.82%
Geode Capital Management, LLC
2.4%
Northern Trust Corp
1.11%
See all

Gilead Sciences Inc. News & Key Events

  • img

    Today's Timeline - 05 August

    Wed, 09:42 PM

    -

    AIDS Healthcare Foundation criticizes Gilead's HIV drug pricing and access policies, raising concerns over affordability in low-income countries.

    Thu, 01:20 AM

    -

    Morgan Stanley maintains Buy rating on Gilead, citing strong fundamentals and HIV franchise momentum with a $165 price target.

Insights on Gilead Sciences Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Gilead Sciences, Inc. has shown positive revenue growth over the last two quarters. Revenue increased from $6.95 billion to $7.80 billion, reflecting an average increase of 10.8% per quarter.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, GILD stock has moved up by 3.0%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Eli Lilly & Co. has given 125.6% return, outperforming this stock by 55.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, AstraZeneca PLC has given 110.7% return, outperforming this stock by 97.6%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Gilead Sciences, Inc. has experienced a decline in net profit for the last four quarters. The profit has decreased from $3.05 billion to -$10.49 billion, indicating an average decrease of 218.4% each quarter. This consistent downward trend highlights significant financial challenges for the company.

About Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
OrganisationGilead Sciences Inc.
Headquarters333 Lakeside Drive, Foster City, CA, United States, 94404
IndustryDrug Manufacturers - General
CEOMr. Daniel Patrick O'Day
E-voting on sharesClick here to vote

Key Management of Gilead Sciences Inc.

Name

Title

Mr. Andrew D. Dickinson

Executive VP & CFO

Ms. Johanna Mercier

Chief Commercial & Corporate Affairs Officer

Dr. Dietmar P. Berger M.D., Ph.D.

Chief Medical Officer

Ms. Erin E. Burkhart

Senior VP, Controller & Chief Accounting Officer

Ms. Keeley M. Cain Wettan

Executive VP, General Counsel of Legal & Compliance and Secretary

Dr. Linda Slanec Higgins Ph.D.

Senior Vice President of Research, Innovation & Portfolio

Mr. Daniel Patrick O'Day

Chairman & CEO

Ms. Jacquie Ross C.F.A.

Senior Vice President of Treasury & Investor Relations

Ms. Jyoti K. Mehra

Executive Vice President of Human Resources

Dr. Flavius Martin M.D.

Executive Vice President of Research

FAQs

What is Gilead Sciences Inc. share price today?

Gilead Sciences Inc. share price today is $135.88 as on at the close of the market. Gilead Sciences Inc. share today touched a day high of $137.12 and a low of $133.32.

What is the 52 week high and 52 week low for Gilead Sciences Inc. share?

Gilead Sciences Inc. share touched a 52 week high of $157.29 on and a 52 week low of $108.46 on . Gilead Sciences Inc. stock price today i.e. is closed at $135.88,which is 13.61% down from its 52 week high and 25.28% up from its 52 week low.

What is Gilead Sciences Inc.'s market capitalisation today?

Gilead Sciences Inc. market capitalisation is $0.16T as on .

How to invest in Gilead Sciences Inc. Stock (GILD) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gilead Sciences Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Gilead Sciences Inc. Shares that will get you 0.0110 shares as per Gilead Sciences Inc. share price of $135.88 per share as on August 13, 2026 at 1:29 am IST.

What is the minimum amount required to buy Gilead Sciences Inc. Stock (GILD) from India?

Indian investors can start investing in Gilead Sciences Inc. (GILD) shares with as little as ₹95.32 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹953.20 in Gilead Sciences Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Gilead Sciences Inc. share’s latest price of $135.88 as on August 13, 2026 at 1:29 am IST, you will get 0.0736 shares of Gilead Sciences Inc.. Learn more about fractional shares .

What are the returns that Gilead Sciences Inc. has given to Indian investors in the last 5 years?

Gilead Sciences Inc. stock has given 90.8% share price returns and 28.24% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?